Epizyme out to raise $140M; Chelsea names Oliveto as permanent CEO;

@FierceBiotech: Is Bristol-Myers fading back in its hot race with Merck for PD-1 lead? More | Follow @FierceBiotech

@JohnCFierce: Scoff warning: This buyout story relates to experimental dendritic cell cancer vaccine tech. Story | Follow @JohnCFierce

@DamianFierce: ICYMI: Big-time pharma contractor Catalent lines up for an IPO worth $100M--or much more. Article | Follow @DamianFierce

@EmilyMFierce: Study: mutations in Russian TB strain make it drug-resistant. Story via Wired UK | Follow @EmilyMFierce

> Just weeks after seeing its share price rocket up on news of a Celgene milestone payment, Epizyme ($EPZM) is looking to raise $140 million through the sale of stock for its development work in epigenetics. Filing

> Chelsea Therapeutics, which has gone through a number of ups and downs in its development of Northera, named Joseph Oliveto as the biotech's permanent CEO. Story

> Celsion ($CLSN) says the latest overall survival data from its post-hoc analysis of results from its Phase III HEAT study of ThermoDox supports continued clinical development. Release

Medical Device News

@FierceMedDev: U.K. researchers unveil an artificial pancreas they've been developing for 20 years. News | Follow @FierceMedDev

@MichaelGFierce: St. Jude places its first Nanostim leadless pacemaker in a U.K. patient. Story | Follow @MichaelGFierce

@EmilyWFierce: Johnson & Johnson's Animas launches new combination insulin pump in Canada. Article | Follow @EmilyWFierce

@GalenMoore: Pfizer misses its endpoint for 2 PhIII trials of dacomitinib in non-small cell lung cancer. Release | Follow @GalenMoore

> 23andMe's genome test raises more questions, this time for ancestry results. Item

> Varian, Toshiba announce a $515M medical imaging deal. More

> Edwards nabs EU nod for next-gen Sapien as competition mounts. News

Pharma News

@FiercePharma: Merck KGaA CFO jumps ship amid turnaround he helped engineer; shares slide. Story | Follow @FiercePharma

@TracyStaton: Q4 sales up, 2013 down, esp in US: Bristol-Myers Squibb Reports 4th Quarter and Full Year 2013 Results. Release | Follow @TracyStaton

@EricPFierce: Ranbaxy will need new markets as FDA closes window on U.S., analysts predict. Piece | Follow @EricPFierce

@CarlyHFierce: Bristol-Myers impresses with trimmed-down costs, pumped-up sales. Story | Follow @CarlyHFierce

> Merck KGaA CFO jumps ship amid turnaround he helped engineer; shares slide. Story

> Spurred by pricey Gilead hep C drug, payers cook up new cost-control moves. Article

> Pfizer weighs legal options as PA Supreme Court revives Redux design-defect suit. News

> Ranbaxy will need new markets as FDA closes window on U.S., analysts predict. More

CRO News

> Report: Indian clinical trials fell 93% last year. Story

> CRO Genae reaches into Germany for device trials. News

> ResearchDx pushes into the Middle East for diagnostics development. Article

> Catalent lines up for an IPO worth $100M--or much more. More

> Covance adding 500 jobs in U.K. nutrition expansion. Piece

> Datatrak, Clinverse team up for clinical trial tech. Item

Biotech IT News

> The clinical trial technology sector could top $5B by 2018, report says. Story

> Sony teams with Illumina to crack the Japanese genome market. More

> Report: Pharma is missing a Big Data opportunity by ignoring social media. News

> The NCI is offering $20M to pilot projects that move cancer genomics into the cloud. Piece

> U.K. to digitize patient health records and sell access to biopharma researchers. Article

> Novo Nordisk taps Trialbee for online recruitment of trial patients. Item

Suggested Articles

Biogen stunned the biotech world Tuesday when it said it would file aducanumab for approval. Now that the dust has settled, what are analysts saying?

Biocytogen uses chromosome engineering for the in situ replacement of mouse antibody genes with the human counterparts.

Eli Lilly is canning the lead program for the crown jewel of its $1.6 billion Armo buyout after the drug put up a poor showing in pancreatic cancer.